Get the Stockscreener App
130.55
0.86%
1.11
After Hours:
130.55
Biogen Inc stock is traded at $130.55, with a volume of 1.66M.
It is up +0.86% in the last 24 hours and up +10.07% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$129.44
Open:
$129.035
24h Volume:
1.66M
Relative Volume:
1.00
Market Cap:
$19.13B
Revenue:
$9.82B
Net Income/Loss:
$1.48B
P/E Ratio:
12.89
EPS:
10.13
Net Cash Flow:
$2.30B
1W Performance:
+6.00%
1M Performance:
+10.07%
6M Performance:
-16.31%
1Y Performance:
-43.63%
1-Day Range:
$128.82
$131.13
1-Week Range:
$119.18
$131.13
52-Week Range:
$110.03
$238.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
130.55 | 18.05B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
747.01 | 669.76B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.66 | 357.16B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
184.85 | 332.08B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
112.28 | 211.00B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
68.20 | 290.60B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Rafferty Asset Management LLC Increases Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Ameriprise Financial Inc. Sells 1,006,463 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
ProShare Advisors LLC Raises Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
26,179 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Point72 Hong Kong Ltd - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Lazard Asset Management LLC - MarketBeat
Do Wall Street Analysts Like Biogen Stock? - Barchart.com
Zacks Research Has Pessimistic Outlook of Biogen Q2 Earnings - MarketBeat
Patient Capital Management LLC Has $63.30 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Man Group plc Sells 170,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors on strong trading day - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Captrust Financial Advisors - MarketBeat
Baird Financial Group Inc. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Suvretta Capital Management LLC Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
HSBC Adjusts Price Target on Biogen to $121 From $118, Maintains Hold Rating - marketscreener.com
Siemens Fonds Invest GmbH Raises Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mufg Securities Americas Inc. Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
LMR Partners LLP Purchases 6,379 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FDA approves first blood test for detecting Alzheimer's - marketscreener.com
Eisai Shares Rise as New Alzheimer’s Test Seen Helping Sales - Bloomberg
2,347 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by MJP Associates Inc. ADV - MarketBeat
Centiva Capital LP Sells 4,487 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 14,148 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
4,411 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Sig Brokerage LP - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Ethic Inc. - MarketBeat
Orbimed Advisors LLC Lowers Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Letko Brosseau & Associates Inc. Sells 13,330 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Graham Capital Management L.P. Buys Shares of 13,357 Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FDA Clears Alzheimer's Test: BIIB's Role in Treatment - GuruFocus
FDA clears first blood-based Alzheimer's test (BIIB:NASDAQ) - Seeking Alpha
US FDA clears first blood test for Alzheimer's detection - marketscreener.com
FDA Clears First Blood Test to Diagnose Alzheimer’s Disease - Bloomberg
US FDA clears first blood test to detect Alzheimer's disease - marketscreener.com
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Gotham Asset Management LLC - MarketBeat
Hudson Bay Capital Management LP Decreases Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Deutsche Bank AG - MarketBeat
Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands - insights.citeline.com
Rep. Robert Bresnahan, Jr. Sells Off Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Eisai says Leqembi is headed for 'demand expansion phase' in US - Endpoints News
Goldman Sachs maintains Biogen buy rating, $196 target By Investing.com - Investing.com UK
Dementia Drugs Market Projected To Witness Massive Growth, - openPR.com
BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance - Yahoo Finance
Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
Eisai, Biogen to Shift Some Lecanemab Ingredient Production to US Amid Tariff Concerns - marketscreener.com
Immunomodulators Market Detailed In New Research Report 2025 | - openPR.com
Biogen Sues Ex-Collaborator Over Rights to Drug Tech - USA Herald
Biogen Sues Ex-Collaborator Over Rights To Drug Tech - Law360
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.26%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):